General Description
Methyldopate Hydrochloride is the ester prodrug of methyldopa, an centrally-acting alpha-2 adrenergic agonist used primarily in the management of hypertension, including hypertension in pregnancy. The esterification to methyldopate improves aqueous solubility and allows for intravenous administration, providing a useful option for hypertensive emergencies when oral intake is not feasible.
Mechanism of Action
Methyldopate Hydrochloride is hydrolyzed in plasma to methyldopa (alpha-methyl-DOPA), which acts as a false neurotransmitter. Alpha-methyldopa is decarboxylated by aromatic L-amino acid decarboxylase (ALAAD) to alpha-methylnorepinephrine (alpha-MN), a potent agonist at central alpha-2 adrenergic receptors. Activation of central alpha-2 receptors in the brainstem reduces sympathetic outflow, decreasing peripheral vascular resistance, heart rate, and blood pressure without causing significant reduction in renal blood flow.
Application
Methyldopate Hydrochloride is indicated for the treatment of hypertensive crises, particularly in hospitalized patients, and is considered one of the preferred antihypertensives for managing severe hypertension in pregnancy (gestational hypertension and pre-eclampsia) due to its extensive safety data in this population.